Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1

Journal of Virology

Volumn 86, Issue 2, 2012, Pages 961-971

  Şahin, Gülşen Özkaya ^a   Holmgren, Birgitta ^a,g   da Silva, Zacarias ^b   Nielsen, Jens ^c   Nowroozalizadeh, Salma ^d,e   Esbjörnsson, Joakim ^f   Månsson, Fredrik ^g   Andersson, Sören ^d   Norrgren, Hans ^g   Aaby, Peter ^b,c   Jansson, Marianne ^a,e   Fenyö, Eva Maria ^a  

^a LUND UNIVERSITY   (Sweden)

^b Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Guinea-Bissau)

^c STATENS SERUM INSTITUT   (Denmark)

^d SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f LUND UNIVERSITY   (Sweden)

^g LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; GUINEA-BISSAU; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; IMMUNOGENICITY; MALE; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS LOAD; VIRUS NEUTRALIZATION;

ADULT; AGED; ANTIBODIES, NEUTRALIZING; COHORT STUDIES; FEMALE; GUINEA-BISSAU; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; MALE; MIDDLE AGED;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 84856890445     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06315-11     Document Type: Article

References (55)

1. Albert J, et al. 1990. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4:107-112.
2. Albert J, Bottiger B, Biberfeld G, Fenyo EM. 1989. Replicative and cytopathic characteristics of HIV-2 and severity of infection. Lancet i:852-853.
3. Albert J, et al. 1990. Replicative capacity of HIV-2, like HIV-1, correlates with severity of immunodeficiency. AIDS 4:291-295.
4. Andersson S, et al. 2000. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch. Intern. Med. 160:3286-3293.
5. Andersson S, Norrgren H, Dias F, Biberfeld G, Albert J. 1999. Molecular characterization of human immunodeficiency virus (HIV)-1 and -2 in individuals from Guinea-Bissau with single or dual infections: predominance of a distinct HIV-1 subtype A/G recombinant in West Africa. Virology 262:312-320.
6. Arendrup M, et al. 1992. Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J. Acquir. Immune Defic. Syndr. 5:303-307.
7. Ariyoshi K, et al. 1996. A community-based study of human immunodeficiency virus type 2 provirus load in rural village in West Africa. J. Infect. Dis. 173:245-248.
8. Bangham CR. 2000. The immune response to HTLV-I. Curr. Opin. Immunol. 12:397-402.
9. Barouch DH. 2008. Challenges in the development of an HIV-1 vaccine. Nature 455:613-619.
10. Benjouad A, Gluckman JC, Rochat H, Montagnier L, Bahraoui E. 1992. Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160. J. Virol. 66:2473-2483.
11. Bjorling E, et al. 1993. Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology 193:528-530.
12. Bjorndal A, et al. 1997. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71:7478-7487.
13. Bussmann BM, et al. 2010. Loss of HIV-specific memory B-cells as a potential mechanism for the dysfunction of the humoral immune response against HIV. Virology 397:7-13.
14. Costa CI, Morgado MG, Santos VG, Bongertz V. 1996. HIV-1 isolation from plasma specimens. HEC/FIOCRUZ AIDS Clinical Research Group. Mem. Inst. Oswaldo Cruz 91:745-746.
15. da Silva ZJ, et al. 2008. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing? AIDS 22:1195-1202.
16. Doria-Rose NA, et al. 2010. Breadth of human immunodeficiency virusspecific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84:1631-1636.
17. Esbjornsson J, et al. 2010. Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease-indication of an evolving epidemic in West Africa. Retrovirology 7:23.
18. Fenyo EM, et al. 2009. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One 4:e4505.
19. Frost SD, et al. 2005. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl. Acad. Sci. U. S. A. 102:18514-18519.
20. Gody M, Ouattara SA, de The G. 1988. Clinical experience of AIDS in relation to HIV-1 and HIV-2 infection in a rural hospital in Ivory Coast, West Africa. AIDS 2:433-436.
21. Gunthard HF, et al. 2009. HIV-1 superinfection in an HIV-2-infected woman with subsequent control of HIV-1 plasma viremia. Clin. Infect. Dis. 48:e117- e120.
22. Jaffar S, et al. 1997. Rate of decline of percentage CD4_ cells is faster in HIV-1 than in HIV-2 infection. J. Acquir. Immune Defic. Syndr Hum. Retrovirol. 16:327-332.
23. Karlsson I, et al. 2003. HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS 17:2561-2569.
24. Klasse PJ, Sanders RW, Cerutti A, Moore JP. 20 May 2011. How can HIV-type-1-Env immunogenicity be improved to facilitate antibodybased vaccine development? AIDS Res. Hum. Retroviruses. [Epub ahead of print.]
25. Klein J, Bjorkman P. 2010. Few and far between: how HIV may be evading antibody avidity. PLoS Pathog. 6:e1000908.
26. Larsen O, et al. 1998. Declining HIV-2 prevalence and incidence among men in a community study from Guinea-Bissau. AIDS 12: 1707-1714.
27. Laurén A, Fenyö E. 2008. Implications from the SIV model in understanding HIV neutralization. Future HIV Ther. 2:47-58.
28. Lemey P, et al. 2003. Tracing the origin and history of the HIV-2 epidemic. Proc. Natl. Acad. Sci. U. S. A. 100:6588-6592.
29. Mansson F, et al. 2009. Prevalence and incidence of HIV-1 and HIV-2 before, during and after a civil war in an occupational cohort in Guinea-Bissau, West Africa. AIDS 23:1575-1582.
30. Marlink RG, et al. 1988. Clinical, hematologic, and immunologic crosssectional evaluation of individuals exposed to human immunodeficiency virus type-2 (HIV-2). AIDS Res. Hum. Retroviruses 4:137-148.
31. McCaffrey RA, Saunders C, Hensel M, Stamatatos L. 2004. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J. Virol. 78: 3279-3295.
32. Mikell I, et al. 2011. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7:e1001251.
33. Morner A, et al. 1999. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J. Virol. 73:2343-2349.
34. Pereyra F, et al. 2009. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J. Infect. Dis. 200: 984-990.
35. Polzer S, Dittmar MT, Schmitz H, Schreiber M. 2002. The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization. Virology 304:70-80.
36. Popper SJ, et al. 1999. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J. Infect. Dis. 180:1116-1121.
37. Poulsen AG, et al. 1993. HIV-2 infection in Bissau, West Africa, 1987-1989: incidence, prevalences, and routes of transmission. J. Acquir. Immune Defic. Syndr. 6:941-948.
38. Poulsen AG, et al. 1989. Prevalence of and mortality from human immunodeficiency virus type 2 in Bissau, West Africa. Lancet i:827-831.
39. Powell RL, Kinge T, Nyambi PN. 2010. Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus. J. Virol. 84:9415-9426.
40. Richman DD, Wrin T, Little SJ, Petropoulos CJ. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 100:4144-4149.
41. Rodriguez SK, et al. 2007. Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)-and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections. J. Virol. 81: 5331-5338.
42. Rubsamen-Waigmann H, et al. 1994. Standard conditions of virus isolation reveal biological variability of HIV type 1 in different regions of the world. WHO Network for HIV Isolation and Characterization. AIDS Res. Hum. Retroviruses 10:1401-1408.
43. Sather DN, et al. 2009. Factors associated with the development of crossreactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769.
44. Schonning K, Jansson B, Olofsson S, Nielsen JO, Hansen JS. 1996. Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer. Virology 218:134-140.
45. Seaman MS, et al. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84: 1439-1452.
46. Shi Y, Albert J, Francis G, Holmes H, Fenyo EM. 2002. A new cell line-based neutralization assay for primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 18:957-967.
47. Shi Y, et al. 2005. Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. J. Gen. Virol. 86:3385-3396.
48. Simek MD, et al. 2009. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83:7337-7348.
49. Thomas ER, Shotton C, Weiss RA, Clapham PR, McKnight A. 2003. CD4-dependent and CD4-independent HIV-2: consequences for neutralization. AIDS 17:291-300.
50. Tremblay M, Wainberg MA. 1990. Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. J. Infect. Dis. 162:735-737.
51. van Gils MJ, Schuitemaker H. 2010. Correlations between HIV-1 subtypes and HIV-1 antibody neutralization sensitivity: significant for vaccine development? Curr. HIV Res. 8:579-586.
52. Vinner L, et al. 2011. Sequence analysis of HIV-1 isolates from Guinea-Bissau: selection of vaccine epitopes relevant in both West African and European countries. APMIS 119:487-497.
53. Von Gegerfelt A, Albert J, Morfeldt-Manson L, Broliden K, Fenyo EM. 1991. Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease. Virology 185:162-168.
54. Wei X, et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312.
55. Zhu P, et al. 2006. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441:847-852.